A practical healthcare scenario
Synthetic healthcare data can support development and exploratory analysis when direct access to patient records is restricted. Consider an illustrative hospital network building a capacity-planning tool with an external software partner. Developers need realistic admission sequences, ward transfers and discharge events, but most do not need identifiable clinical histories to test screens, interfaces and scheduling logic.
This example is not a clinical trial, a customer success story or evidence that synthetic records can replace clinical validation. It describes how to scope a safer development dataset. The hospital should distinguish interface testing from research and clinical decision support, because the consequences of an inaccurate example differ substantially between those activities.
Define the minimum useful dataset
Start with the questions the software must answer. A bed-planning interface may need admission timing, ward capacity and plausible lengths of stay, without detailed diagnoses or narrative notes. Reducing scope can lower both disclosure exposure and modelling complexity. It also makes evaluation clearer: developers can test whether transfers and occupancy calculations behave correctly.
Clinical specialists should identify relationships that must remain valid, such as discharge following admission and procedures occurring within an appropriate encounter. Terminology teams should review coding systems and version differences. The ontology and taxonomy guide explains why shared definitions matter when datasets from several organisations are combined.
Protect the source environment
Generation may require processing real health information, so approval, lawful access and security controls remain necessary. Restrict training to an approved environment and minimise who can inspect original records or trained artefacts. Record the purpose, data flows, processors and retention arrangements. The involvement of a generator does not remove the need for a contextual data protection assessment.
Pay particular attention to unusual diagnoses, rare treatment combinations, precise dates and free text. These features may make a patient recognisable even when direct identifiers are absent. The ICO cautions that synthetic data can remain vulnerable to inference and linkage. Decide whether a controlled workspace is more appropriate than distributing downloadable files.
Generate clinically coherent records
Choose methods that represent longitudinal structure rather than treating each encounter as an unrelated row. Preserve links between patients, encounters, observations and transfers where those links are needed. Use explicit constraints to reject impossible event sequences. A dataset that matches the overall average length of stay can still be unsuitable if it produces incoherent individual pathways.
Separate observed patterns from deliberately constructed scenarios. A hypothetical surge in admissions may be valuable for capacity testing, but it should be labelled as a scenario rather than a statistically estimated future event. Our synthetic generation guide provides a reproducible process for documenting these assumptions and their validation.
Validate against the permitted purpose
For software testing, validate schema compatibility, event ordering, missing values, boundary cases and expected interface responses. For analytical exploration, compare relevant aggregate measures, temporal patterns and relationships with approved real reference data. Include clinical review, because statistical similarity alone may miss combinations that practitioners immediately recognise as implausible.
If a predictive model is developed, evaluate it on appropriately governed real data before any clinical use. Generated patients cannot establish safety, effectiveness or fairness in an actual population. Check representation across relevant groups and settings, and report where small samples limit conclusions. Do not infer that a successful capacity-planning dataset is suitable for diagnosis or treatment recommendations.
Manage release and downstream access
Publish a dataset card describing the intended use, generation process, known limitations and disclosure assessment. Make restrictions clear to the software partner: a testing dataset should not become an unreviewed training corpus or a public demonstration without approval. Version releases so that an issue can be traced to the exact generator and source snapshot.
Establish a process for reporting suspicious examples and withdrawing a release. Repeat privacy and utility checks when source populations, generation settings or recipient access conditions change. Good data integration governance helps preserve lineage across the original systems, the synthetic release and the applications that consume it.
Keep research claims proportionate
Researchers may use a synthetic release to develop code or explore a proposed method before requesting access to real records. That can reduce unnecessary access, but analytical findings still need confirmation using appropriate evidence. A relationship that appears in generated data may reflect the generator's assumptions or source limitations rather than a clinically meaningful association.
Describe the release's population coverage, coding conventions and missingness in the supporting documentation. If certain pathways or groups were excluded, state that clearly. External collaborators should understand whether the dataset is intended for technical familiarisation, method development or a more rigorously validated analytical purpose. Ethical review and clinical governance should follow the actual proposed use rather than the comforting label of artificial data.
Measure a bounded outcome
For this scenario, useful outcomes include fewer production-data copies in development, shorter provisioning times and broader automated test coverage. Evaluate whether developers can reproduce defects without requesting real patient records. Include the effort required for clinical review and privacy assessment in the business case rather than presenting synthetic data as a cost-free shortcut.
Once the first use is validated, assess additional purposes separately instead of extending approval by assumption. The synthetic data overview is a useful starting point for cross-functional discussions. ALLFLOW's synthetic data offering can be explored against explicit requirements, with clinical evidence, lawful processing and human accountability remaining essential.